Suppr超能文献

分离酶活性分布可作为 TKI 治疗慢性髓性白血病患者主要分子反应和 CD34 细胞增殖的标志物。

Separase activity distribution can be a marker of major molecular response and proliferation of CD34 cells in TKI-treated chronic myeloid leukemia patients.

机构信息

Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Hämatologie und Onkologie, III. Medizinische Klinik, Wissenschaftliches Labor, Universitätsklinikum Mannheim GmbH, Pettenkoferstraße 22, 68169, Mannheim, Germany.

出版信息

Ann Hematol. 2020 May;99(5):991-1006. doi: 10.1007/s00277-020-04007-4. Epub 2020 Apr 6.

Abstract

Separase, a cysteine endopeptidase, is a key player in mitotic sister chromatid separation, replication fork dynamics, and DNA repair. Aberrant expression and/or altered separase proteolytic activity are associated with aneuploidy, tumorigenesis, and disease progression. Since genomic instability and clonal evolution are hallmarks of progressing chronic myeloid leukemia (CML), we have comparatively examined separase proteolytic activity in TKI-treated chronic phase CML. Separase proteolytic activity was analyzed on single cell level in 88 clinical samples and in 14 healthy controls by a flow cytometric assay. In parallel, BCR-ABL1 gene expression and replication fork velocity were measured by qRT-PCR and DNA fiber assays, respectively. The separase activity distribution (SAD) value indicating the occurrence of MNCs with elevated separase proteolytic activity within samples was found to positively correlate with BCR-ABL1 gene expression levels and loss of MMR (relapse) throughout routine BCR-ABL1 monitoring. Analyses of CD34 cells and MNCs fractionized by flow cytometric cell sorting according to their separase activity levels (H- and L-fractions) revealed that CD34 cells with elevated separase activity levels (H-fractions) displayed enhanced proliferation/viability when compared with cells with regular (L-fraction) separase activity (mean 3.3-fold, p = 0.0011). BCR-ABL1 gene expression positivity prevailed in MNC H-fractions over L-fractions (42% vs. 8%, respectively). Moreover, expanding CD34 cells of H-fractions showed decreased replication fork velocity compared with cells of L-fractions (p < 0.0001). Our data suggests an association between high separase activity, residual BCR-ABL1 gene expression, and enhanced proliferative capacity in hematopoietic cells within the leukemic niche of TKI-treated chronic phase CML.

摘要

有丝分裂姐妹染色单体分离、复制叉动态和 DNA 修复过程中,分离酶(一种半胱氨酸内肽酶)是关键因子。异常表达和/或分离酶蛋白水解活性改变与非整倍体、肿瘤发生和疾病进展有关。由于基因组不稳定性和克隆进化是进展性慢性髓性白血病(CML)的标志,我们比较研究了 TKI 治疗慢性期 CML 中的分离酶蛋白水解活性。通过流式细胞术检测,在 88 例临床样本和 14 例健康对照者中分析了分离酶蛋白水解活性。同时,通过 qRT-PCR 和 DNA 纤维分析分别测量了 BCR-ABL1 基因表达和复制叉速度。分离酶活性分布(SAD)值表示在样本中存在具有升高的分离酶蛋白水解活性的多形核细胞(MNCs)的发生率,与 BCR-ABL1 基因表达水平以及整个常规 BCR-ABL1 监测中错配修复(复发)的丧失呈正相关。根据分离酶活性水平(H 和 L 亚群)对 CD34 细胞和 MNC 进行流式细胞分选后分析,结果显示与常规分离酶活性(L 亚群)的细胞相比,具有升高的分离酶活性水平(H 亚群)的 CD34 细胞的增殖/活力增强(平均值 3.3 倍,p=0.0011)。在 MNC H 亚群中,BCR-ABL1 基因表达阳性率高于 L 亚群(分别为 42%和 8%)。此外,与 L 亚群相比,H 亚群中扩增的 CD34 细胞的复制叉速度降低(p<0.0001)。我们的数据表明,在 TKI 治疗慢性期 CML 的白血病龛内造血细胞中,高分离酶活性、残留的 BCR-ABL1 基因表达与增强的增殖能力之间存在关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa66/7196950/fccfed28550c/277_2020_4007_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验